Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

NCT06686394 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

81

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms
Breast Cancer

Interventions

BIOLOGICAL: Patritumab deruxtecan
BIOLOGICAL: Trastuzumab
BIOLOGICAL: Trastuzumab Biosimilar
BIOLOGICAL: Pertuzumab
BIOLOGICAL: Tucatinib

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]